

Ming Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4335637/publications.pdf>

Version: 2024-02-01

88
papers

5,346
citations

136740

32
h-index

91712

69
g-index

91
all docs

91
docs citations

91
times ranked

6292
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. <i>Gastroenterology</i> , 2007, 132, 2328-2339.	0.6	743
2	Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2007, 245, 36-43.	2.1	424
3	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 413-420.	0.7	305
4	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. <i>JAMA Oncology</i> , 2019, 5, 953.	3.4	292
5	CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. <i>Oncogene</i> , 2018, 37, 6025-6040.	2.6	211
6	Radiofrequency Ablation versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas 2 cm or Smaller: A Retrospective Comparative Study. <i>Radiology</i> , 2012, 262, 1022-1033.	3.6	203
7	High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. <i>Human Pathology</i> , 2009, 40, 381-389.	1.1	191
8	Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 60-69.	1.8	153
9	Micrometastases of Solitary Hepatocellular Carcinoma and Appropriate Resection Margin. <i>World Journal of Surgery</i> , 2004, 28, 376-381.	0.8	150
10	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 150-160.	0.8	137
11	A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1437-1445.	1.2	122
12	Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 702-709.	0.2	106
13	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 63, 122-130.	1.8	101
14	Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4780-4791.	3.2	95
15	Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. <i>Cancer Communications</i> , 2018, 38, 1-12.	3.7	92
16	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	1.4	91
17	Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. <i>Chinese Journal of Cancer</i> , 2017, 36, 83.	4.9	90
18	GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0168907.	1.1	79

#	ARTICLE	IF	CITATIONS
19	Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 595-604.	1.9	78
20	A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 928-936.	1.3	70
21	MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. <i>Cancer Letters</i> , 2016, 383, 85-93.	3.2	66
22	EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 63, 863-873.	1.8	65
23	Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 59-68.	3.0	64
24	Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 547-555.	1.2	60
25	Hepatic Resection versus Transarterial Lipiodol Chemoembolization as the Initial Treatment for Large, Multiple, and Resectable Hepatocellular Carcinomas: A Prospective Nonrandomized Analysis. <i>Radiology</i> , 2011, 259, 286-295.	3.6	58
26	Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2013, 8, e60444.	1.1	58
27	Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. <i>FASEB Journal</i> , 2019, 33, 8759-8770.	0.2	54
28	Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 618206.	1.3	53
29	Cell-adaptable dynamic hydrogel reinforced with stem cells improves the functional repair of spinal cord injury by alleviating neuroinflammation. <i>Biomaterials</i> , 2021, 279, 121190.	5.7	53
30	Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. <i>World Journal of Gastroenterology</i> , 2010, 16, 264.	1.4	46
31	Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Hepatology Research</i> , 2011, 41, 553-563.	1.8	42
32	An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 313-321.	1.8	41
33	Immunosuppressive Immature Myeloid Cell Generation Is Controlled by Glutamine Metabolism in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1605-1618.	1.6	38
34	Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 734-743.	0.9	35
35	Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. <i>Hepatology International</i> , 2010, 4, 537-547.	1.9	33
36	Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. <i>European Radiology</i> , 2016, 26, 2078-2088.	2.3	33

#	ARTICLE	IF	CITATIONS
37	Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 167-176.	1.8	30
38	MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 1227-1239.	3.6	29
39	Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 35116-35128.	0.8	29
40	Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 866-874.	1.4	28
41	Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 41.	1.8	27
42	Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. <i>Chinese Journal of Cancer</i> , 2016, 35, 28.	4.9	26
43	NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>International Journal of Cancer</i> , 2019, 145, 662-670.	2.3	26
44	Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3043-e3043.	2.7	25
45	Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. <i>Cancer Medicine</i> , 2018, 7, 5339-5350.	1.3	25
46	NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 228.	1.8	25
47	Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1267-1276.e1.	0.2	24
48	Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 1430-1437.	0.4	23
49	Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 787-797.	3.3	23
50	The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 5990-6000.	0.8	23
51	Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 3122.	1.4	22
52	Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. <i>Medical Oncology</i> , 2013, 30, 696.	1.2	21
53	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 837-843.	0.6	21
54	MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 263-273.	1.2	21

#	ARTICLE	IF	CITATIONS
55	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 349-357.e2.	0.2	21
56	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3207-3216.	2.0	21
57	Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. <i>British Journal of Cancer</i> , 2016, 115, 1039-1047.	2.9	20
58	Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. <i>Oncotarget</i> , 2016, 7, 38845-38856.	0.8	20
59	Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. <i>Journal of Translational Medicine</i> , 2012, 10, 245.	1.8	19
60	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1068-1077.e2.	0.2	19
61	Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4239-4246.	1.0	18
62	Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. <i>Chinese Journal of Cancer</i> , 2015, 34, 205-16.	4.9	17
63	Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 475-482.	0.8	17
64	Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 631-645.	0.7	15
65	Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619461.	1.3	14
66	Identification of the Pyroptosis-Related Gene Signature for Overall Survival Prediction in Patients With Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 742994.	1.8	14
67	Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2465-2476.	1.1	13
68	Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2025-2032.	0.9	13
69	Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 665-671.	1.2	13
70	Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e44061.	1.1	13
71	LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2010, 16, 2046.	1.4	13
72	Prognostic significance of sodium-potassium ATPase regulator, FXD3, in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 15, 3024-3030.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus. <i>Metabolomics</i> , 2019, 15, 156.	1.4	10
74	Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4200-4213.	1.3	9
75	A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 95.	1.8	8
76	Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 78-83.	0.2	7
77	A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. <i>Oncology Letters</i> , 2015, 10, 2787-2794.	0.8	6
78	Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply. <i>JAMA Oncology</i> , 2019, 5, 1806.	3.4	4
79	Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. <i>European Journal of Radiology</i> , 2021, 142, 109890.	1.2	4
80	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 226-244.	2.0	4
81	Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 253-261.	1.8	2
82	Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro. <i>Cancer Cell International</i> , 2021, 21, 610.	1.8	2
83	Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	0.6	2
84	The Surgical Margin in Liver Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2007, 246, 691-692.	2.1	1
85	Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. <i>Liver International</i> , 2016, 36, 1516-1524.	1.9	1
86	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 73-77.	0.9	1
87	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 580-581.	3.0	0
88	Reply to J. Mei et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200020.	0.8	0